No Data
No Data
Emerging Markets stock digest: BTM rebounded for the first time in six days and reached a daily maximum limit, while Ribomic significantly rebounded.
<303A> visumo 2340 -700 stop-limit. After updating the all-time high in the morning, it has shifted to a selling dominance due to a pause in buying. Visumo went public on December 26 last year, debuting at 1,036 yen, which is 34.5% above the offering price (770 yen). Since then, it has continued to hit the daily upper limit, and on the morning of the 8th, it surged to 3,110 yen, nearly three times the debut price. The operating profit Financial Estimates for the fiscal year ending March 2025 is expected to be 0.073 billion yen, which is a 291.8% increase compared to the previous term.
Individual stock information.
Justplan <4287.T> continued to rise for six days, remaining unchanged amid significant gains. A stock buyback limit of 600,000 shares (4.93% of issued shares excluding treasury stock) and a 200 million yen buyback program were established. The acquisition period is from January 8 to July 31. Additionally, 283,700 treasury shares currently held (2.23% of issued shares before retirement) will be retired effective January 15. McDonald's <2702.T> declined continuously. The preliminary monthly revenue for December was announced, showing same-store sales decreased by 0.4% compared to the same month last year, marking the fifth consecutive month of decline.
Hot Stocks Digest (Morning Session): JINSHD, Adastria, Ribomic, ETC.
JINSHD <3046>: 6,800 yen (+420 yen) significantly continues its upward trend. The previous day announced the monthly trends for December. Same-store sales increased by 24.4% compared to the same month last year, marking 23 consecutive months of positive growth and 8 consecutive months of double-digit increases. It seems that high-priced commodities in both lenses and frames have performed well due to the increased inbound demand leading up to the year-end and the effects of the promotional campaign conducted within the month. The continuation of the strong sales momentum is evaluated positively.
Sanbio - Significantly rebounded, human bone marrow-derived processed mesenchymal stem cells improved cortical excitability in rats with focal cerebral ischemia.
Significant rebound. It has been announced that a paper demonstrating that the company's main development product, human bone marrow-derived processed mesenchymal stem cells "Vandefitem Cell (SB623)", improves cortical excitability in rats with local brain ischemia has been published in the American scientific journal "Molecular Therapy". According to the paper, it was found that the transplantation of Vandefitem Cell alleviates the hyperexcitability of the cerebral cortex caused by brain ischemia and restores normal brain function.
Soft tone, with the decline in U.S. stocks and the rise in U.S. long-term interest rates acting as a burden.
[Emerging Markets Individual Stock Global Strategy] Today's Emerging Markets are expected to show a weak performance. Yesterday, on the 7th, the U.S. Stocks market saw the Dow Inc drop 178.20 points (-0.42%) to 42,528.36, continuing its decline. The rise of Semiconductors NVIDIA (NVDA) initially drove the market higher in the morning; however, the company's stock later turned downward, becoming a burden on the market. Additionally, the stronger-than-expected JOLT job openings and ISM non-manufacturing index raised concerns that the pace of interest rate cuts may slow, leading to a rise in long-term interest rates.
SanBio's Stem Cell Research Shows Promise for Neurological Disorder Treatments
No Data